Pharmacy Benefits Management Services Home

in a primary prevention population vs. 5.4 ASCVD events/1,000 patients . treated /year. with moderate dose statins in primary and secondary prevention studies. A. difference of 0.5 events . prevented/1000 patients treated/ year. (See Table 1).3, 9. Click link. for a. summary of each clinical trial in the Appendix, beginning on page 6: ................
................